Hold Ranbaxy in portfolio, says Atul Badkar

One should hold Ranbaxy Laboratories in the portfolio and from current level it can go to Rs 475, says Atul Badkar, VP - Institutional Equities - Derivatives Desk at Edelweiss Securities.

May 15, 2013 / 10:41 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Atul Badkar, VP - Institutional Equities - Derivatives Desk at Edelweiss Securities told CNBC-TV18, "In Ranbaxy the news that came out yesterday or the day before yesterday was the only negative that we were expecting in the stock and from here onwards quite a bit of negatives have already been priced in."

He further added, "Going forward we expect margins to expand. Fundamentally, we have a buy on the stock and even technically it has been consolidating in that range and we were bullish a little earlier than yesterday’s move, but even from these levels I think Rs 475 is very easily gettable, so like a 4-5 percent upside within the entire pharma pack, not just from a trading perspective but even fundamentally we believe Ranbaxy should be like a hold in the portfolio."

first published: May 15, 2013 10:41 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347